Author Archives: admin
Merit Medical Acquires Biolife Delaware
Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports. Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profile Merit reaffirms full-year 2025 […]
BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
New BD FACSDiscover™ A8 Cell Analyzer Brings Leading-Edge Capabilities to Wider Range of Scientists across Academia and Biopharma
KyphoLift Debuts at ISMRM 2025: Transforming Patient Positioning for Safer, More Accurate Imaging
Visit ISMRM Booth H19 for Hands-On Demonstrations of the KyphoLift™ and KyphoWedge™ Systems
Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills
BioUtah president and CEO, Kelvyn Cullmore, recently penned an op-ed published in the Deseret News.
Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis
The WRAPSODY CIE is designed to help physicians prolong functional vascular access in hemodialysis patients.
Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial
In the AVG cohort of the US pivotal trial, the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) achieved 60.2% target lesion primary patency (TLPP) at 12 months.
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk
Peer-Reviewed Article Reporting DiscGenics’ Cell Therapy Phase I/II Study Results Receives International Journal of Spine Surgery Best Paper Award
Salt Lake City, UT – April 9, 2025 – DiscGenics, Inc., a privately held, late-stage clinical, biopharmaceutical company developing allogeneic, cell-based, regenerative therapies for musculoskeletal degeneration, today announced that the double-blind, peer-reviewed article, “Allogeneic Disc Progenitor Cells Safely Increase Disc Volume and Improve Pain, Disability, and Quality of Life in Patients With Lumbar Disc Degeneration—Results […]
BREAKING GROUND ON COMPREHENSIVE CANCER CENTER IN VINEYARD
Huntsman Cancer Institute at the University of Utah (the U) broke ground on its second Comprehensive Cancer Center on Tuesday, April 8, advancing construction of a new facility wholly dedicated to delivering prevention, hope, and healing to cancer patients. Situated in Vineyard, in the heart of Utah County, the Huntsman Cancer Institute site will reduce […]
The ‘Father of Modern Food and Drug Law,’ Peter Hutt, Joins EVŌQ Nano Board of Directors
Hutt Brings Decades of Regulatory Insight to Help Advance Nanoparticle Technology Platform SALT LAKE CITY, Utah (April 9, 2025) — EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, material, and textile science industries, today announced the appointment of Peter Barton Hutt, former FDA Chief Counsel, to its board of directors. Widely […]
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine’s REAL Space, the world’s largest source of make-on-demand small […]
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsSalt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has […]
